ASH 2020: Dr. Alexey Danilov on Inhibiting MCL1 to Overcome Resistance to Ibrutinib and Venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma or CLL/SLL and Other Non-Hodgkin’s Lymphoma or NHL
This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
The American Society of Hematology is a non-profit organization involving blood cancer physicians, researchers and healthcare stakeholders and is the world leader in promoting and supporting clinical and scientific hematology research. Its Annual December Meeting provides a prestigious forum for the peer-reviewed presentation of ground-breaking and cutting-edge data. In this video, Dr. John Pagel states emphatically that this CLL data should be known by all CLL patients and their caregivers.
Related posts